2019
Blood tumor mutational burden (bTMB) and tumor PD-L1 as predictive biomarkers of survival in MYSTIC: First-line durvalumab (D) ± tremelimumab (T) versus chemotherapy (CT) in metastatic (m) NSCLC.
Rizvi N, Cho B, Reinmuth N, Lee K, Luft A, Ahn M, van den Heuvel M, Dols M, Vicente D, Smolin A, Moiseyenko V, Antonia S, Nakagawa K, Goldberg S, Kim E, Walker J, Raja R, Liu F, Scheuring U, Peters S. Blood tumor mutational burden (bTMB) and tumor PD-L1 as predictive biomarkers of survival in MYSTIC: First-line durvalumab (D) ± tremelimumab (T) versus chemotherapy (CT) in metastatic (m) NSCLC. Journal Of Clinical Oncology 2019, 37: 9016-9016. DOI: 10.1200/jco.2019.37.15_suppl.9016.Peer-Reviewed Original ResearchBlood tumor mutational burdenPredictive biomarkersPD-L1Tumor cell PD-L1 expressionPD-L1 IHC assaysAppropriate predictive biomarkersFirst-line durvalumabPD-L1 TCTumor PD-L1PD-L1 expressionPlatinum-based chemotherapyTumor mutational burdenExploratory analysisMetastatic NSCLCTreatment decisionsMutational burdenChemotherapyIHC assaysTC expressionBiomarkersSmall sample sizeExpression levelsFurther investigationOSAdditional cutoffs
2015
Phase III, randomized, open-label study of durvalumab (MEDI4736) in combination with tremelimumab or durvalumab alone versus platinum-based chemotherapy in first-line treatment of patients with advanced/metastatic NSCLC: MYSTIC
Rizvi N, Barlesi F, Brahmer J, Felip E, Forde P, Garassino M, Goldberg S, Vansteenkiste J, Jarkowski A, McIntosh S, Zhao L, Antonia S. Phase III, randomized, open-label study of durvalumab (MEDI4736) in combination with tremelimumab or durvalumab alone versus platinum-based chemotherapy in first-line treatment of patients with advanced/metastatic NSCLC: MYSTIC. Journal For ImmunoTherapy Of Cancer 2015, 3: p171. PMCID: PMC4646121, DOI: 10.1186/2051-1426-3-s2-p171.Peer-Reviewed Original Research